RPCEC00000089已完成4 期
sing the monoclonal antibody Nimotuzumab in treating patients with squamous cell carcinoma of head and neck in advanced stages.
Center of Molecular Immunology(CIM)0 个研究点开始时间: 2009年10月22日最近更新:
适应症
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Non-randomized controlled trial. Masking: Open. Control group: Uncontrolled. Assignment: Other. Purpose: Treatment
入排标准
- 年龄范围
- 18 years 至 none（—）
- 性别
- All
入选标准
- •1.Age greater than or equal to 18 years. 2.Life expectancy of at least 12 weeks. 3.General status ECOG 0-2. 4.Patients give their consent to participate in the study in writing.
排除标准
- •1.Patient at the time of inclusion is receiving another investigational drug. 2.Pregnancy,postpartum or breastfeeding. 3.History of hypersensitivity to any of the components of the pharmaceutical formulation of Nimotuzumab. 4.Presence of a second primary tumor, except basal or squamous cell carcinoma of the skin and neck carcinoma in situ treated.
研究者
相似试验
已完成
不适用
Study of the mechanism of action of Nimotuzumab in patients with head and neck tumorsocally advanced head and neck epithelial tumorsHead and Neck NeoplasmsNeoplasms, Glandular and EpithelialCarcinoma, Squamous CellReceptor, Epidermal Growth FactorRPCEC00000241Center of Molecular Immunology (CIM)30
Unknown
3 期
Nimotuzumab in Combination With Chemoradiation for Nasopharyngeal CancerNasopharyngeal CancerNCT01074021Biotech Pharmaceutical Co., Ltd.480
Unknown
2 期
Nimotuzumab Plus Docetaxel and Capecitabine Versus Docetaxel and Capecitabine in the Treatment of Breast Cancer PatientsBreast CancerNCT01939054Chinese Academy of Medical Sciences90
Unknown
1 期
Pharmacokinetics Study of Nimotuzumab in Patients With Solid TumorsSolid TumorsNCT02395068Biotech Pharmaceutical Co., Ltd.40
招募中
不适用
Concurrent and Adjuvant Nimotuzumab Combined With Induction Chemotherapy Plus Chemoradiation in Nasopharyngeal CarcinomaNasopharyngeal Carcinoma by AJCC V8 StageNCT05717790Fourth Affiliated Hospital of Guangxi Medical University288